ebselen has been researched along with Hypomania in 1 studies
ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In/outpatients (n = 68) aged 18-70, experiencing mania or hypomania, were assigned to 3 weeks ebselen (600 mg bd) (n = 33) or placebo (n = 35)." | 9.34 | A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania. ( Cowen, PJ; Godlewska, BR; Holder, AA; MacDonald, O; Shanyinde, M; Sharpley, AL; Singh, N; Williams, C, 2020) |
| " In/outpatients (n = 68) aged 18-70, experiencing mania or hypomania, were assigned to 3 weeks ebselen (600 mg bd) (n = 33) or placebo (n = 35)." | 5.34 | A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania. ( Cowen, PJ; Godlewska, BR; Holder, AA; MacDonald, O; Shanyinde, M; Sharpley, AL; Singh, N; Williams, C, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sharpley, AL | 1 |
| Williams, C | 1 |
| Holder, AA | 1 |
| Godlewska, BR | 1 |
| Singh, N | 1 |
| Shanyinde, M | 1 |
| MacDonald, O | 1 |
| Cowen, PJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Parallel Group, Double Blind, Placebo Controlled, Add on Clinical Trial to Investigate Whether the Lithium Mimetic, Ebselen, Can Reduce Symptoms of Hypomania and Mania in Bipolar Patients[NCT03013400] | Phase 2 | 60 participants (Actual) | Interventional | 2017-10-01 | Completed | ||
| Does the IMPase Inhibitor, Ebselen, Affect Emotional Processing and Brain Myo-inositol in Treatment-resistant Depression?[NCT05117710] | Phase 1 | 50 participants (Anticipated) | Interventional | 2021-04-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for ebselen and Hypomania
| Article | Year |
|---|---|
A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania.
Topics: Adult; Aged; Antimanic Agents; Azoles; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combinat | 2020 |
A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania.
Topics: Adult; Aged; Antimanic Agents; Azoles; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combinat | 2020 |
A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania.
Topics: Adult; Aged; Antimanic Agents; Azoles; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combinat | 2020 |
A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania.
Topics: Adult; Aged; Antimanic Agents; Azoles; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combinat | 2020 |